Indeed, the lineage transition to a NE subtype is one mechanism by which PCa evades androgen receptor (AR)-targeting treatment by shifting its cellular phenotype from an AR-dependent adenocarcinoma to an AR-indifferent NE or small-cell carcinoma. This evidence concerns the gene AR and adenocarcinoma.